TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Steven Cohen's SAC Capital Discloses New XenoPort Stake Market Folly submits:Due to activity on May 14th, 2010, Steven Cohen's hedge fund firm SAC Capital has disclosed a new position in XenoPort (XNPT). As per a 13G filed with the SEC, SAC Capital shows a 6.0% ownership stake in the company with 1,819,228 shares. Again, this is a new position for the fund as it did not show ownership in its previous portfolio disclosure as of March 31st, 2010.Please also keep in mind that SAC is a trading oriented firm and moves in and out of positions much quicker than the fundamental hedge funds we typically track. Of the prominent hedge funds we cover, we've only seen one other firm previously own shares of XNPT. Lee Ainslie's firm had a position in XenoPort, but Maverick Capital just sold out in the first quarter. Regarding other recent portfolio activity from Steven Cohen's firm, we saw that it raised its stake in Inspire Pharma (ISPH) and updated its position in The Talbots (TLB).Complete Story » seekingalpha.com |
PPD and Microsoft to Deliver Innovative REMS Solution Based on Microsoft Technologies (Business Wire) WILMINGTON, N.C.----PPD, Inc. and Microsoft Corp. today announced they have entered into an agreement to jointly implement an innovative technology solution designed to improve efficiency in managing U.S. us.rd.yahoo.com |
A Reintroduction to Savient's Krystexxa Rockford Coscia submits: On September 17, Savient's (SVNT) Krystexxa (pegloticase) faces what could be the end of a tumultuous journey to approval. Krystexxa has had an especially bumpy go of it, with soaring high of a 14-1 panel approval and crushing low of an FDA complete response letter. Investors may be sick from the rollercoaster ride and are certainly looking for relief from the FDA. I want to provide a brief summary of what Krystexxa is, what it has gone through, and what I expect as we get closer to this important catalyst date.Complete Story » seekingalpha.com |
Sanofi-Aventis to Lay Off 1,700 U.S. Employees Sanofi-Aventis said it is eliminating 1,700 jobs in its U.S. pharmaceutical business in a restructuring triggered by generic competition and other factors. online.wsj.com |
Genomic Health to Announce Third Quarter 2010 Financial Results and Host Conference Call on Monday, November 8, 2010 [PR Newswire] - Genomic Health, Inc. today announced that the company will host a conference call and webcast on Monday, November 8 at 4:30 p.m. Eastern Time to discuss its third quarter 2010 financial results. us.rd.yahoo.com |